About Garuda Therapeutics
Garuda Therapeutics is a private company based in Cambridge, Massachusetts, incorporated in 2021 in Delaware. It has reported $157,958,224 raised in three offerings on Form D since September 2021. Its chief executive is Adam Craig.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 17, 2024 | Oct 31, 2024 | $47,709,955target not set | 16 | $2.9M | Equity, OptionsRule 506(b) | Form D ↗ |
| Jan 23, 2023 | Feb 3, 2023 | $62,124,935of $62.8M target | 13 | $4.7M | EquityRule 506(b) | Form D ↗ |
| Sep 9, 2021 | Sep 24, 2021 | $48,123,334of $71.7M target | 23 | $2.0M | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $157,958,224 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Garuda Therapeutics's Form D filed Oct 31, 2024.
GM
Geoff Meyerson
Director
RK
Raymond Kelleher
Director
EA
Eric Aguiar
Director
SL
Steve Liapis
Director
RS
Rahul Singhvi
Director
DK
David Kirske
Executive officer
CG
Carl Gordon
Director
Also a director at ADARx Pharmaceuticals, Avenzo Therapeutics and BlossomHill Therapeutics.
AC
Adam Craig
President and CEO, director
Earlier filings also listed Laurence Reid (director, last listed Feb 2023), Dhvanit Shah (chief executive officer and president, director, last listed Feb 2023), Daniel Janse (director, last listed Feb 2023) and Shaan Gandhi (director, last listed Sep 2021).